

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Sale Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the Sale Shares will be made in the United States.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

(1) SALE OF EXISTING SHARES BY A SUBSTANTIAL SHAREHOLDER (2) CHANGE IN SHAREHOLDING (3) RESIGNATION OF DIRECTORS AND CHANGE OF AUTHORIZED REPRESENTATIVE

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

SALE OF EXISITING SHARES BY A SUBSTANTIAL SHAREHOLDER

The Board has been informed by Prime United, a substantial shareholder of the Company, that:

- (1) on 4 June 2014 (after the close of market), Prime United entered into (i) a placing agreement with a placing agent who is a third party independent from the Company (the "Placing Agent"), (ii) a sale and purchase agreement with Mr. Qu Jiguang, a Director and substantial shareholder of the Company and (iii) a sale and purchase agreement with the Purchaser, pursuant to which, Prime United agreed to sell respectively 514,686,000 Shares to third parties, 110,000,000 Shares to Mr. Qu Jiguang and 145,300,000 Shares to the Purchaser (collectively the "Sale Shares") at a price of HK\$2.75 each (collectively the "Sales"). The Sale Shares represent approximately 26.28% of the total issued share capital of the Company as at the date of this announcement.

- (2) Mr. Qu Jiguang has undertaken not to dispose of his shareholding in the Company (including any Shares arising from the exercise of any options held by Mr. Qu Jiguang) for a period from 4 June 2014 to 180 days after the date of this Announcement.
- (3) Mr. Wu Qin has undertaken not to dispose of his shareholding in the Company (including any Shares arising from the exercise of any options held by Mr. Wu Qin) for a period from 4 June 2014 to 180 days after the date of this Announcement.

Immediately before the Sales, Prime United directly owns 769,986,000 Shares, representing approximately 26.28% of the issued share capital of the Company. Immediately upon completion of the Sales, Prime United will no longer be interested, directly or indirectly, in any Shares and will cease to be a substantial shareholder of the Company.

Prime United informed the Board that the Sales were made based on its own business decision.

The Board does not expect the Sales to have any material impact on the business and operations of the Group.

CHANGES IN SHAREHOLDING

Set out below is a table showing the shareholding structure of the Company (i) immediately before the Sales and (ii) immediately after the completion of the Sales.

	Immediately before the Sales		Immediately after the completion of the Sales	
	<i>No. of Shares</i>	<i>Approximate % of issued share capital</i>	<i>No. of Shares</i>	<i>Approximate % of issued share capital</i>
Prime United (<i>Note (a)</i>)	769,986,000	26.28	0	0.00
Purchaser	0	0.00	145,300,000	4.96
Mr. Qu Jiguang (<i>Note (b)</i>)	724,310,000	24.72	834,310,000	28.47
Other independent placees	0	0.00	514,686,000	17.57
Mr. Wu Qin	18,504,000	0.63	18,504,000	0.63
Other public Shareholders	1,417,125,385	48.37	1,417,125,385	48.37
Total	2,929,925,385	100	2,929,925,385	100

Notes:

- (a) Prime United is held as to about 8.86% by Mr. Wu Qin, an executive Director, as to about 4% by Mr. Xie Yunfeng, an executive Director, as to about 2.41% by Mr. Huang Chao, a director of Xi'an Lijun and as to about 84.73% by Mr. Wu Qin, Mr. Xie Yunfeng and Mr. Huang Chao who jointly hold such shares on trust for approximately 3,000 individuals who are present and former employees or their respective estates of Xi'an Lijun and Rejoy Group. Mr. Wu Qin, Mr. Xie Yunfeng and Mr. Huang Chao are also directors of Prime United. Xi'an Lijun is a subsidiary of the Company. Rejoy Group is a company established in the PRC with limited liability and 100% owned by State-owned Assets Supervision and Administration Commission of the People's Government of Xi'an.

- (b) Mr. Qu Jiguang is an executive Director. By virtue of Part XV of the SFO, Mr. Qu Jiguang is deemed to be interested in the 721,710,000 Shares held by CPCL. CPCL is held as to 72.93% by Mr. Qu Jiguang and as to 27.07% by 39 other shareholders.

RESIGNATION OF DIRECTORS

The Board has been informed that Mr. Wu Qin has resigned as an executive Director and chairman of the Board with effect from 4 June 2014 in order to pursue other personal interests. Mr. Wu continues to hold executive roles in Xi'an Lijun.

The Board has also been informed that Mr. Xie Yunfeng has resigned as an executive Director with effect from 4 June 2014 in order to pursue other personal interests. Mr. Xie continues to hold executive roles in Xi'an Lijun.

Each of Mr. Wu Qin and Mr. Xie Yunfeng has confirmed that he has no disagreement with the Board, and there are no other matters concerning his resignation that need to be brought to the attention of the shareholders of the Company.

CHANGE OF AUTHORIZED REPRESENTATIVE

The Board also announces that Mr. Xie Yunfeng has resigned as Authorized Representative of the Company and Mr. Chan Ka Kit, the Chief Financial Officer and Company Secretary, has been appointed as Authorized Representative of the Company, in each case with effect from 4 June 2014.

The Board would like to take this opportunity to thank Mr. Wu Qin and Mr. Xie Yunfeng for their valuable contributions and service to the Company during their tenure of office.

On 4 June 2014, Mr. Qu has been elected by the Board as the chairman of the Company.

Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the Shares.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings when used herein:

“Board”	the board of Directors
“CPCL”	China Pharmaceutical Company Limited, a company incorporated in Samoa with limited liability, a substantial shareholder of the Company
“Company”	Lijun International Pharmaceutical (Holding) Co., Ltd. (stock code: 2005), a company incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on the Main Board of the Stock Exchange

“Director(s)”	director(s) of the Company
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Prime United”	Prime United Industries Limited, a company incorporated in British Virgin Islands with limited liability, a substantial shareholder of the Company
“PRC”	the People’s Republic of China, which for the purpose of this announcement, excludes Hong Kong, Macau and Taiwan.
“Purchaser”	a corporate investor independent of and not connected with the connected persons of the Company as defined in the Listing Rules, and not being a connected person of the Company
“Rejoy Group”	Rejoy Group Limited Liability Company, a company incorporated in PRC with limited liability and 100% owned by State-owned Assets Supervision and Administration Commission of the People’s Government of Xi’an
“SFO”	Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
“Share(s)”	ordinary share(s) of HK\$0.02 each in the share capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Xi’an Lijun”	Xi’an Lijun Pharmaceutical Co., Ltd., a company incorporated in PRC with limited liability, a directly-held wholly-owned subsidiary of the Company
“%”	per cent.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 4 June 2014

As at the date of this announcement, the Board comprises of Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.